LifeSci Biotechnology Clinical Trials Index
Effective at the market close on August 28, 2025, ITOS will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.
On July 21, 2025, iTeos Therapeutics announced it would be acquired by Concentra Biosciences for $10.047/share in cash plus a CVR (contingent value right).